Physician profile
Frank Cotter
NPI 1932101037
$15,105.09
in general payments reported to CMS, 2019-2025
25 companies · $5,991 in 2025
The $5,991 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $512 · 2021: $510 · 2022: $1,244 · 2023: $1,742 · 2024: $4,349 · 2025: $5,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,113 · Travel and Lodging: $3,290 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,112.88 |
| Travel and Lodging | $3,290.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $8,456.59 | 2019-2025 | Preserflo Microshunt, Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Alcon Vision LLC | $2,069.01 | 2019-2025 | Simbrinza, Ngenuity, Clareon |
| Abbvie INC. | $1,900.39 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| New World Medical,INC. | $518.26 | 2022-2023 | |
| Allergan, INC. | $476.20 | 2019-2022 | |
| Ocular Therapeutix, INC. | $356.65 | 2023-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $313.46 | 2022-2023 | Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.28 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $127.81 | 2019-2021 | |
| Genentech, INC. | $126.17 | 2024 | Vabysmo |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $95.33 | 2019 | |
| Quidel Corporation | $79.23 | 2021 | |
| Horizon Therapeutics Plc | $61.21 | 2023 | Tepezza |
| Biotissue Holdings INC. | $47.01 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $46.00 | 2021 | |
| Thea Pharma INC. | $45.47 | 2023-2024 | Iyuzeh |
| Harrow Eye, LLC | $34.46 | 2023-2024 | Iheezo |
| Seagen INC. | $22.43 | 2023 | Tivdak |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $17.00 | 2024 | Oxervate |
| Amgen INC. | $16.99 | 2024 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $15.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.